Note: Although this FDA-483 is an
accurate representation of the original FDA-483 issued to the firm, it is not an exact
copy. Slight modifications to the original FDA-483 have been made to accommodate its
conversion to the HTML format. A scanned copy of the original FDA-483 is available in PDF format on
this website. |
DEPARTMENT OF
HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION |
DISTRICT OFFICE ADDRESS AND PHONE NUMBER
6000 Metro Drive, Suite 101
Baltimore, Maryland 21215 |
DATE(S) OF INSPECTION:4/22 - 12/20/02 |
| FEI NUMBER:1000123507 |
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED
TO:Ramesh Thadani, Executive Vice President and
Chief Executive Officer |
FIRM
NAME
American National Red Cross/Biomedical Services |
STREET
ADDRESS
1616 Fort Myer Drive |
CITY,
STATE AND ZIP CODE
Arlington, Virginia 22209 |
TYPE OF
ESTABLISHMENT INSPECTED
National Headquarters of a Licensed Blood Bank |
INADEQUATE INVESTIGATION OF
POTENTIAL PROBLEMS WITH PRACTICES RELATED TO DONOR DEFERRAL RATES
- Several regions implemented policies tracking
donor deferral rates for health history reasons by employee, tracking hematocrit deferral
rates by employee and closely observing trained employees. The hotline reports
indicate a potential problem presented by current management practices related to donor
deferral rates. However, BHQ failed to determine whether this is a system problem and to
take corrective action to prevent recurrence:
ARC #[REDACTED]: The records of investigation provided by ARC indicate a
report was received that donors with low hematocrits were being accepted. Results were
being re-read into acceptance by a second individual.
ARC #[REDACTED]: The records of investigation provided by ARC indicate an
employee reported that managers were instructed to verify the hematocrit readings made by
staff. Region reported managers were instructed to review the number of hematocrit
deferrals by each staff member and if the number for any employee was
excessive to observe the employee.
ARC #[REDACTED]: The records of investigation provided by ARC indicate an
employee asked how to lower her history deferral rate without jeopardizing the safety of
the blood supply and without providing false information. The employee stated
it was the regions policy to hold deferrals against collection employees on their
performance evaluations. The employee believes this would seem to foster wrongdoing on the
part of the collection staff. Collection staff might be tempted to lie about donors
histories or qualifications to donate so they will be allowed to donate when in fact they
should be deferred. The employee also stated that collection staff might destroy blood
donation records for donors they had to defer, in order to lower their deferral rates.
ARC #[REDACTED]: The records of investigation provided by ARC indicate an
employee reported that they are being reprimanded when their deferral rate is too high and
are instructed by management to improve by decreasing the number of deferrals.
[REDACTED]: The records of investigation provided by ARC indicate
employees have reported that since converting only to the finger stick to determine iron
levels, the deferral rate has dramatically increased and they are being blamed for this
increase. Employees report that management is consistently monitoring them.
ARC #[REDACTED]: The records of investigation provided by ARC indicate an
employee reported that management informed them that their deferral rates are too high,
especially for low iron readings. Employee reported that they are required to have a nurse
oversee a second test to check hemoglobin levels.
ARC #[REDACTED]: The records of investigation provided by ARC indicate an
employee reported that management is instructing employees to accept allogeneic donors
with iron levels under 38 percent.
INVESTIGATION OF SUSPECTED POST
TRANSFUSION HEPATITIS (fatality):
- Procedures do not require a thorough
investigation of the occurrence of a clinically significant infection or
|
| SEE REVERSE OF THIS PAGE |
EMPLOYEE(S) SIGNATURE
[Handwritten] Initials: MTC, LSM, SJW |
EMPLOYEE(S)
NAME AND TITLE [Handwritten]
Mary T. Carden, Investigator
Linda S. Mattingly, Investigator
Stephany J. Wesley, Investigator |
DATE ISSUED
12/20/02 |
FORM FDA 483 (8/00) PREVIOUS EDITION OBSOLETE INSPECTIONAL
OBSERVATIONS
| Reverse Text on Page: The observations of objectional conditions and practices listed
on the front of this form are reported:
- Pursuant to Section 704(b) of the Federal Food, Drug and
Cosmetic Act, or
- To assist firms inspected in complying with the Acts and
regulations enforced by the Food and Drug Administration.
|
| Section 704(b) of the Federal Food, Drug, and Cosmetic
Act (21 USC374(b)) provides: "Upon
completion of any such inspection of a factory, warehouse, consulting laboratory, or other
establishment, and prior to leaving the premises, the officer or employee making the
inspection shall give to the owner, operator, or agent in charge a report in writing
setting forth any conditions or practices observed by him which, in his judgement,
indicate that any food, drug, device, cosmetic in such establishment (1) consists in whole
or in part of any filthy, putrid, or decomposed substance or (2) has been prepared,
packed, or held under insanitary conditions whereby it may have become contaminated with
filth, or whereby it may have been rendered injurious to health. A copy of such report
shall be sent promptly to the Secretary." |
Web page created by ORA Web Team 12/20/2002
|